NCT03881696: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
- State
- Completed
- Phase
- Phase 3
- People
- 458 taking part
- Started
- 22 Jul 2019
- Primary completion
- 13 Mar 2023
- Arms
- Stage 2: Omalizumab + Placebo OIT
- Results
- Posted on the registry
- 19 Mar 2019: Trial registered
- 22 Jul 2019: Trial started
- 4 Jun 2024: Trial results posted
- 1 Jul 2025: Trial completed